Sedation and weight gain may also be more prominent. Clozapine can cause reversible neutropenia which may progress to a potentially fatal agranulocytosis; strict monitoring of white blood cell counts is essential.
Eosinophilia may also occur.
Extrapyramidal disorders, including tardive dyskinesia appear to be rare with clozapine. Clozapine has a little effect on prolactin secretion. Clozapine appears to have a greater epileptic potential than chlorpromazine but a comparable risk of cardiovascular effects such as tachycardia and orthostatic hypotension. In rare cases circulatory collapse with cardiac and respiratory arrest has occurred, and hypertension has also been reported. Clozapine is also associated with an increased risk of developing myocarditis that may, in rare cases, be fatal; cardiomyopathy and pericarditis have also been reported.
Additional side-effects of clozapine include dizziness. hypersalivation (particularly at night), headache, nausea, vomiting, constipation (which in few cases has led to gastro-intestinal obstruction and paralytic ileus), urinary incontinence and retention, anxiety, confusion, fatigue, and transient fever which may be distinguished from signs of impending agranulocytosis. There have been also rare reports of dysphagia, parotid gland enlargement, delirium, thromboembolism, acute pancreatitis, hepatitis and cholestatic jaundice, and very rarely fulminant hepatic necrosis. Isolated cases of acute interstitial nephritis have been reported. Abnormalities of glucose homeostasis and the onset of diabetes mellitus occur uncommonly; severe hyperglycemia, sometimes leading to ketoacidosis has been reported rarely. Many of the adverse effects of clozapine are most common at the beginning of therapy and may be minimized by gradual increase in dosage.
Patient must seek medical attention immediately at the first sign of any adverse drug reaction shall appear.
View ADR Reporting Link